tions could lead the sufferers to superior outcome.[9, 10] Nonetheless, the effect of aspirin therapy in patients with non-obstructive CAD has not been established.[113] In this study, we investigated the association among aspirin therapy and threat of all-cause mortality as well as a composite of mortality and coronary revascularization in patients with non-obstructive CAD (19% stenosis) documented by CCTA.
This study followed the principles from the Declaration of Helsinki and was approved by the institutional evaluation board of Seoul National University Hospital (H-1207-080-418). Because the records and facts of study population have been anonymized and de-identified for matching with the third celebration claims information, the requirement of informed consent for every single individual was waived by the institutional evaluation board.
A detailed study protocol was published in our prior paper.[14] In brief, we identified a total of eight,372 consecutive sufferers with non-obstructive CAD (19% stenosis) amongst the cohort of 47,708 consecutive people who underwent CCTA at Seoul National University Hospital, Seoul National University Bundang Hospital, or Seoul National University Hospital Healthcare Gangnam Center from January 2007 to December 2011 (Fig 1). Patients for whom statin or aspirin was prescribed before CCTA (n = ten,316), and the patients who had prior coronary revascularization (n = 354) had been excluded, to eliminate patients with existing coronary heart illness. We also excluded the sufferers with obstructive CAD (50% stenosis; n = 3,095) or typical CCTA benefits (0% stenosis; n = 25,571).
Utilizing the electronic health-related records, we obtained the resident registration numbers of study population with demographic elements and laboratory test final results. The medical record data of study population was linked to the Well being Insurance Assessment and Assessment Service (HIRA) claims data. Considering that HIRA has the universal coverage in the whole Korean population, it consists of all data of health-related service that was provided to every person, which includes date, web-site, medications, diagnosis, procedures, hospitalization and survival.[147] Given that the novel antiplatelet agents for instance ticagrelor and 
prasugrel have been approved by Korean Food and Drug Association in 2013 just after the study duration, information on these agents have been not identified. Individual info of study population was concealed, and an unidentifiable code was employed for matching from the database. The matched data were kept securely at HIRA database. To confirm mortality cases and also the precise date of death, the HIRA data was cross-checked with the database in the Korean Ministry of Security and Public Administration.
The main outcome measure was all-cause mortality throughout follow-up period, along with the secondary outcome was a composite of all-cause mortality and late coronary revascularization (90 days following CCTA; like percutaneous coronary intervention and coronary artery bypass graft operation). The date of initial CCTA was applied as the index date to calculate the time to study outcomes, and follow-up duration of each and every patient was counted in accordance with the first to occasion occurrence order. To decrease verification bias, individuals who underwent early coronary revascularization (90 days right after CCTA) and the patients for whom statin or aspirin was prescribed with or immediately after coronary revascularization have been treated as 1198097-97-0 structure censored at the time of revascularization.[18]
Individuals underwent 64-slice multidetector CT (SOMATOM Sensation 64 and
